|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 111 K Street, NE |
Address2 | Suite 700 |
City | WASHINGTON |
State | DC |
Zip Code | 20002-8110 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 27467-12
|
||||||||
|
6. House ID# 303670000
|
TYPE OF REPORT | 8. Year | 2019 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Max Richtman |
Date | 10/4/2019 1:43:51 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Mandatory Spending Programs. (No bill.) Proposals pertaining to the manner in which funding for the purpose of paying Social Security benefits are appropriated.
Administrative Budget for the Social Security Administration (SSA). H.R. 2740, the Labor, Health and Human Services, Education, Defense, State, Foreign Operations, and Energy and Water Development Appropriations Act, 2020: Administrations proposal for funding SSAs operations for Fiscal Year 2020.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Executive Office of the President (EOP), Office of Management & Budget (OMB), Treasury - Dept of, Natl Economic Council (NEC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Max |
Richtman |
|
|
|
Dan |
Adcock |
|
|
|
Webster |
Phillips |
|
|
|
Lisa |
Swirsky |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Drug Pricing. H.R. 3, the Lower Drug Costs Now Act: Proposals to authorize the Secretary of Health and Human Services (HHS) to negotiate drug prices on behalf of Medicare with pharmaceutical manufactureres. Create a maximum price for any negotiated drug with an international price index (Average International Market price). Require drug manufacturers that refuse to negotiation with HHS to pay a Non-Compliance Fee of 65 percent of the gross sales of the drug in question. Require drug companies that raised the price of a drug in Medicare above the rate of inflation since 2016 to either lower the price or pay the entire price above inflation in a rebate back to the Treasury. Create a $2,000 Medicare beneficiary annual out-of-pocket cost cap for prescription drugs.
Drug Pricing. S. 2543, the Prescription Drug Pricing Reduction Act of 2019: Require pharmaceutical manufacturers to rebate Medicare if they raise their prices for drugs covered by Medicare Parts B and D faster than inflation. Establish an out-of-pocket spending limit in which Medicare beneficiaries would pay no more than $3,100 a year on drug costs. Require Medicare Part D private insurers to pay 60 percent and, drug makers 20 percent, of the costs incurred over the out-of-pocket spending cap. Increase transparency into pharmacy benefit manager practices and manufacturer drug pricing decisions. Provide state Medicaid programs with more authority to contain drug prices.
Drug Pricing. H.R. 1046, the Medicare Negotiation and Competitive Licensing Act: Proposal to allow the Secretary of Health and Human Services to directly negotiate prices for prescription drugs and issue a competitive license allowing other manufacturers to produce the drug for Medicare in the event negotiations fail.
Drug Pricing. S. 1895, the Lower Health Care Costs Act of 2019: Proposals to reduce the cost of prescription drugs including allowing generic drug manufacturers to sue brand-name manufacturers for not selling them samples for testing necessary to get to market; and requiring a drug manufacturer to submit a report to the Secretary of Health and Human Services for each price increase of certain drugs of which the wholesale acquisition cost increase is equal to 10 percent or more over a 12-month period or 25 percent or moreover a 36-month period.
Dementia and Alzheimers Disease. S. 2076/H.R. 4256, Building Our Largest Dementia Infrastructure for Alzheimers Act (BOLD Act): Proposal to apply a public health approach to combat Alzheimers disease and related dementias.
Medicare Observation Status. H.R. 1682/S. 753, the Improving Access to Medicare Coverage Act of 2019: Proposal to count days in the hospital in observation status toward meeting the three-day prior hospitalization requirement for skilled nursing facility care eligibility.
Generic Drug Introduction.
Generic Drug Introduction. H.R. 965, the CREATES Act: Proposal to speed the introduction of generic competition by curbing brand drug maker abuses of safety procedures as a means to limit generic manufacturer access to the drug samples needed to obtain Food and Drug Administration approval.
Health Care Rights Law. Proposed rule to the provision of the Affordable Care Act addressing discrimination based on age, race, color, national origin, English proficiency, disability or sex.
Medicaid Home and Community-Based Services: H.R. 1839, the Medicaid Services Investment and Accountability Act of 2019: Proposal extending the spousal impoverishment protections for home and community-based services until September 2019.
Medicare Prescription Drug Costs. (No bill.) Proposals to reduce amount drug manufacturers must contribute to closing the donut hole in 2019.
Medicare Prescription Drug Costs. (No bill.) Provisions of the United States-Mexico-Canada Agreement (formerly the North American Free Trade Agreement) addressing countries having expansive regulatory approval monopolies for biologic drugs and restricting the ability of Congress to reform patent laws that drive up drug costs for Medicare.
Medicare Coverage Expansion. H.R. 576, the Seniors Have Eyes, Ears, and Teeth Act of 2019; H.R. 1393, the Medicare Dental, Vision, and Hearing Benefit Act of 2019; H.R. 1518, the Medicare Hearing Aid Coverage Act of 2019: Proposals to expand Medicare coverage to include, vision, dental and hearing benefits.
Medicare Open Enrollment. (No bill.) Proposals to ensure the Centers for Medicare and Medicaid Services conducts open enrollment in a way that is unbiased toward the traditional program.
Medicare Part D. (No bill.) Proposals to add an out-of-pocket cap, rationalize the structure of the Part D program, and make the Part D low-income subsidy more generous.
Medigap Reform: H.R. 1394, the Medigap Consumer Protection Act: Proposal to improve quality of coverage and access to Medigap by restoring first dollar coverage and extending guaranteed issue to disabled people and other beneficiairies.
Drug Safety. S. 1895, the Lower Health Care Costs Act of 2019: Proposal to remove requirement that medicines marketed in the U.S. adhere to quality standards established by the U.S. Pharmacopeia. These standards allow biosimilar makers to achieve regulatory certainty and expedite biosimilars to market.
Medicare Enrollment. H.R. 2477/S. 1280, the BENES Act of 2019: Proposal to improve beneficiary education tools and extend funding for state health insurance and assistance programs.
Reducing Health Care Costs: S. 1895, the Lower Health Care Costs Act of 2019: Proposal to eliminate surprise medical billing including out-of-network charges in emergencies.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Centers For Medicare and Medicaid Services (CMS), Administration on Aging, Executive Office of the President (EOP)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Max |
Richtman |
|
|
|
Dan |
Adcock |
|
|
|
Webster |
Phillips |
|
|
|
Lisa |
Swirsky |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code RET
16. Specific lobbying issues
Cost of Living Adjustment (COLAs) Relief. H.R. 860/S. 269, the Social Security 2100 Act; H.R. 1170/S. 478, the Social Security Expansion Act; H.R. 1553, the Fair COLA for Seniors Act of 2019; and H.R. 2302/S. 1132, the Protecting and Preserving Social Security Act: Proposals to adopt the Consumer Price Index for the Elderly (CPI-E) for the purpose of determining COLAs for Social Security beneficiaries.
Social Security Expansion. H.R. 860/S. 269, the Social Security 2100 Act; H.R. 1170/S. 478, the Social Security Expansion Act; H.R. 2302/S. 1132, the Protecting and Preserving Social Security Act; and H.R. 2654, the Strengthening Social Security Act: Proposals to improve benefits and to strengthen Social Security's financing by altering the payroll tax cap, among other changes.
Caregiver Social Security Credits. H.R. 4126, the Social Security Caregiver Credit Act of 2019: Proposal to provide Social Security wage credits for individuals who reduce their participation in the workforce or leave the workforce to provide care to specified family members and relatives.
Supplemental Security Income (SSI) Restoration. H.R. 4280, the Supplemental Security Income Restoration Act of 2019: Proposal to update provisions in the SSI program to reflect inflation since 1972 and to increase the asset limit to $10,000 for an individual and $15,000 for a couple.
Social Security Government Pension Offset and Windfall Elimination Provision. H.R. 141/S. 521, Social Security Fairness Act of 2019: Proposal to repeal the Government Pension Offset and Windfall Elimination Provision.
Social Security Benefit Statement (No bill.) Proposal to have the Social Security Administration resume annual distribution of benefit statements to eligible individuals.
Protecting Seniors from Garnishment. (No bill.) Proposal to protect Social Security beneficiaries from having their Social Security benefits garnished to recover unpaid student loans.
Disability Adjudication. (No bill.) Proposal to stop the Social Security Administration from reinstituting the reconsideration step of the Social Security Disability Insurance adjudication process in the ten states where that step is not used.
Social Security and Supplemental Security Income Disability Benefits Adjudication. (No bill): Comments on regulatory proposals to alter the rules regarding the evaluation of medical evidence for the purpose of adjudicating claims for both Social Security and Supplemental Security Income disability benefits.
Prohibit Payment of Social Security and Supplemental Security Insurance Benefits. (No bill.) Proposal to bar payment of benefits for seniors with outstanding warrants for their arrest.
Social Security Benefit Improvement. (No bill.) Proposal to adjust benefit levels for individuals who have been on the Social Security benefit rolls for many years.
Social Security Office Closures. H.R. 2302/S. 1132, the Protecting and Preserving Social Security Act, H.R. 2901/S. 1616, the Maintain Access to Vital Social Security Services Act: Proposals to protect and preserve Social Securitys network of local field offices from closure or consolidation.
Strengthening Beneficiaries Rights. (No bill.) Various proposals relating to the protection and rights available to Social Security and Supplemental Security Income beneficiaries.
Social Security Disability Insurance Waiting Periods. H.R. 4386/S. 2496, the Stop the Wait Act: Proposal to eliminate the 36-month waiting period for Medicare coverage for disabled individuals and the 5-month waiting period for start of payment of cash benefits.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Social Security Administration (SSA), Administration on Aging, Executive Office of the President (EOP), Justice - Dept of (DOJ), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Max |
Richtman |
|
|
|
Dan |
Adcock |
|
|
|
Webster |
Phillips |
|
|
|
Lisa |
Swirsky |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code GOV
16. Specific lobbying issues
House Select Committee on Aging. (No bill.) Proposal to reestablish the House Select Committee on Aging in the 116th Congress.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Max |
Richtman |
|
|
|
Dan |
Adcock |
|
|
|
Webster |
Phillips |
|
|
|
Lisa |
Swirsky |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |